Interoperability Is Becoming Commercial Distribution Infrastructure
Editorial revision: . Original publication and source dates are retained.
TEFCA scale, BCDA v3, and electronic prior-authorization momentum are changing interoperability from a compliance feature into a distribution and implementation advantage for healthcare companies.
Return to insightsHealthcare AI founders, payer and provider platforms, product leaders, implementation teams, and investors / 2026-07-19
The strategic question
What becomes commercially possible when claims and clinical data can move through national networks and standardized APIs with less bespoke integration?
All network and API milestones are attributed to HHS or CMS. Commercial implications are independent operator analysis.
Executive thesis
Data transport is one part of the implementation cost.
I would value interoperability through the implementation work it removes and the operating decisions it enables. A standard transport mechanism can reduce one category of integration effort while leaving identity resolution, data meaning, permitted use and accountability unresolved. The commercial case should isolate which costs become reusable across customers and which remain specific to each institution.
That distinction determines where a supplier should invest. Reusable connectors can improve onboarding economics, but a connector that depends on undocumented local mappings may only move customization out of the visible project plan. I would measure contract-to-live time alongside exception work after launch, then examine whether the next customer uses the same data and workflow contract. Faster ingestion has limited value if the receiving team still cannot act on the record.
The strategic choice is how much of the capability to own. Standardize transport and common controls where possible; preserve differentiation in reconciliation, decision support and delivery where the company can demonstrate it. Build portability and exit requirements into purchasing, because low initial integration cost can coexist with expensive migration later. Access to data expands an opportunity set; the product still has to earn a place in the buyer’s workflow.
Public facts
HHS reported in February 2026 that nearly 500 million health records had been exchanged through TEFCA, up from roughly 10 million in January 2025.
CMS made BCDA v3 available on July 1, 2026 and set July 30, 2027 as the removal date for access to v1 and v2, giving ACOs a defined migration window for bulk claims data.
CMS announced 29 early-adopter organizations working on electronic prior authorization ahead of 2027 requirements.
My assessment
The commercial advantage is faster implementation and broader reach, not the existence of an API connection.
Standards reduce transport friction but do not eliminate semantic, identity, attribution, workflow, or exception work. Those operating layers remain differentiators.
A product has a stronger implementation case when it converts network data into a reconciled record, an authorized action and evidence of completion. Whether that reduces cost at scale remains a cohort-level question to measure.
Migration events such as BCDA v3 are commercial moments because they force buyers to revisit data architecture, vendor capability, and implementation ownership.
Operating model
Test what becomes reusable after implementation.
Start with one buyer decision and its minimum data requirements. Build reusable mappings and controls, then test whether they reduce implementation time and unresolved work.
Operating framework
- 01
Map the minimum data needed for the buyer decision and the authoritative source for each element.
- 02
Use network and API access to shorten implementation, not to collect data without a clear workflow purpose.
- 03
Translate data into an owned work object, accountable action, and measurable outcome.
- 04
Design identity, consent, provenance, reconciliation, and exception controls before expanding data volume.
- 05
Measure the commercial advantage in launch time, workflow completion, and retained value.
Metrics that matter
- 01
Contract-to-live implementation time
- 02
Data completeness and reconciliation rate
- 03
Time from data availability to accountable action
- 04
Manual integration and exception burden
- 05
Expansion enabled by reusable connectors and data contracts
Buyer implications
Founders should treat interoperability as part of distribution and onboarding strategy.
Buyers should ask how the product resolves conflicting sources and what work happens after ingestion.
Implementation teams should productize mappings, validation, and exception handling rather than rediscovering them for every customer.
Management priorities
Choose one buyer workflow and write the data-to-action contract.
Inventory reusable FHIR, TEFCA, claims, and authorization capabilities.
Instrument data quality, reconciliation, exception handling, and launch time.
Sell the reduced implementation burden and operating result, not standards compliance alone.
Red flags
The roadmap celebrates data access but cannot name the decision it changes.
Each customer still requires a bespoke semantic and workflow implementation.
The company cannot explain provenance, identity, or reconciliation when sources disagree.
CEO and CFO questions
Which implementation bottleneck disappears if this data is available through a standard path?
Who acts on the data and in which system?
How are provenance and conflicting records handled?
What reusable asset remains after the first integration?
Design the data, workflow, implementation, and proof architecture that converts interoperability into faster value.
Turn data access into distributionDiscuss the strategic decision